Epidemiology, control and treatment of multiresistant Gram-negative rods

Drugs

Volumn 52, Issue SUPPL. 2, 1996, Pages 95-102

  Wiedemann, Bernd ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMPICILLIN; CARBAPENEM DERIVATIVE; CEFOTAXIME; CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CIPROFLOXACIN; FOSFOMYCIN; GENTAMICIN; PENICILLIN G; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULFONAMIDE; TETRACYCLINE; TOBRAMYCIN;

ACINETOBACTER; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; BURKHOLDERIA CEPACIA; CONFERENCE PAPER; EPIDEMIOLOGY; ESCHERICHIA COLI; GEOGRAPHIC DISTRIBUTION; GRAM NEGATIVE BACTERIUM; INFECTION CONTROL; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MULTIDRUG RESISTANCE; NONHUMAN; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

ACINETOBACTER; BACTERIA (MICROORGANISMS); BURKHOLDERIA; BURKHOLDERIA CEPACIA; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; NEGIBACTERIA; PSEUDOMONAS; PSEUDOMONAS AERUGINOSA; STENOTROPHOMONAS MALTOPHILIA;

EID: 0029825238     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199600522-00020     Document Type: Conference Paper

References (9)

1. Cassel GH. New and emerging infections in the face of a funding crisis. ASM News 1994; 60: 254-4
2. Lee LA, Puhr ND, Maloney EK, et al. Increase in antimicrobial-resistant Salmonella infections in the United States. 1989-1490. J Infect Dis 1994; 170: 128-34
3. Verhoef J. Worldwide resistance against antibiotics. Int J Antimicrob Agents 1994; 4/3: 141-2
4. American Society for Microbiology (1995). Report of the ASM Task Force on Antibiotic Resistance. Antimicrob Agents Chemother 1995; Suppl. 6: 1-23
5. Wiedemann B, Grimm H. Susceptibility to antibiotics: species incidence and trends. In: Lorian V, editor. Antibiotics in laboratory medicine. 4th ed. Baltimore, Maryland: 1996. In press
6. Kresken M, Kayser FH, Mittermeyer H, et al. Resistenzsituation bei klinisch wichtigen Bakterienarten gegenüber Chemotherapeutika in Mitteleuropa, Ergebnisse einer multizentrischen Studie aus dem Jahr 1990. Chemotherapie J 1994; 4: 211-3
7. Kresken M, Hafner D, Mittermayer H, et al. and the Study Group 'Bacterial Resistance' of the Paul-Ehrlich-Society for Chemotherapy. Prevalence of fluoroquinolone resistance in Europe. Infection 1994; 22 Suppl.: 90-7
8. Kresken M. Prävalenz der Resistenz bei klinisch wichtigen Bakterienspezies gegenüber älteren und neueren Antibiotika in Europa. Ergebnisse einer multizentrischen Studie der Arbeitsgemeinschaft "Resistenz" der Paul-Ehrlich-Gesellschaft für Chemotherapie e.V. aus dem Jahre 1990. Bundesgesundheitsblatt 1995; 5: 170-8
9. Vincent J-L, Bihari DJ, Suter PM, et al. for the EPIC International Advisory Committee. The prevalence of noso comial infection in intensive care units in Europe JAMA 1995; 8: 639-44